Biotech News

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Absci Corporation (ABSI)Absci Corporation2026-09-24 12:00 ESTClinical readout

Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

ABSIAbsci Corporation2026-09-24 12:00 EST

Stock data

Close: 10.27 USD
Market cap: 990M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Related news

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic

Absci Corporation

Recent company news

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Absci to Participate in Upcoming Investor Conferences

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Stock data